Discontinued — last reported Q2 '18
Deferred Tax Assets
Bristol-Myers Squibb Deferred Tax Assets increased by 6.8% to $4.96B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 37.5%, from $3.61B to $4.96B. Over 4 years (FY 2020 to FY 2024), Deferred Tax Assets shows an upward trend with a 38.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests potential future tax savings, while a decrease may indicate the utilization of these assets or valuation allowances.
Detailed definition
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between acc...
Peer comparison
Standard accounting item for large corporations with complex tax structures and international operations.
deferred_tax_assetsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $650.00M | $684.00M | $1.44B | $1.42B | $1.34B | $1.33B | $1.34B | $1.32B | $1.57B | $1.51B | $2.77B | $2.72B | $3.32B | $3.61B | $4.24B | $4.00B | $4.65B | $4.96B |
| QoQ Change | — | +5.2% | +110.4% | -1.5% | -5.7% | -0.6% | +1.1% | -2.0% | +19.4% | -3.7% | +82.8% | -1.6% | +22.0% | +8.6% | +17.4% | -5.6% | +16.3% | +6.8% |
| YoY Change | — | — | — | — | +105.7% | +94.3% | -6.6% | -7.1% | +17.6% | +13.9% | +106.0% | +106.8% | +111.4% | +138.4% | +53.0% | +46.8% | +39.8% | +37.5% |
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's deferred tax assets?
- Bristol-Myers Squibb (BMY) reported deferred tax assets of $4.96B in Q3 2025.
- How has Bristol-Myers Squibb's deferred tax assets changed year-over-year?
- Bristol-Myers Squibb's deferred tax assets increased by 37.5% year-over-year, from $3.61B to $4.96B.
- What is the long-term trend for Bristol-Myers Squibb's deferred tax assets?
- Over 4 years (2020 to 2024), Bristol-Myers Squibb's deferred tax assets has grown at a 38.2% compound annual growth rate (CAGR), from $1.16B to $4.24B.
- What does deferred tax assets mean?
- Future tax benefits that the company expects to realize.